Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fujii, Y.
Right arrow Articles by Kawashima, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fujii, Y.
Right arrow Articles by Kawashima, Y.
NEUROLOGY 1985;35:577
© 1985 American Academy of Neurology

Acetylcholine receptor antibody production by bone marrow cells in a patient with myasthenia gravis

Yoshitaka Fujii, MD, Yasumasa Monden, MD, Jumpei Hashimoto, MD, Kazuya Nakahara, MD and Yasunaru Kawashima, MD

First Department of Surgery, Osaka University Medical School, Osaka, Japan.

We briefly report antiacetylcholine receptor antibody production by cultured bone marrow cells (4.9 ± 0.9 fmol/106 cells/wk, mean ± SD) in a 65-year-old man with myasthenia gravis without thymoma. Lymphocytes from peripheral blood, thymus, and lymph nodes produced less antibody (1.8 ± 0.1, 0.9 ± 0.3, and 1.0 ± 0.4, respectively). The thymus was involuted, and the effect of thymectomy was doubtful 6 months postoperatively.

Address correspondence and reprint requests to Dr. Fujii, First Department of Surgery, Osaka University Medical School. 1–1–50 Fukushima, Osaka 553, Japan.

Supported by a grant from the Ministry of Education of Japan.

Accepted for publication August 6, 1984.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1985 by AAN Enterprises, Inc.